Mutation status of the Ig heavy chain variable region genes (IGHV) has a major impact on the prognosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma and has implications for treatment stratification in clinical trials [18,19,20,21]. This evidence concerns the gene SLC3A2 and B-cell chronic lymphocytic leukemia.